Objective: This study was designed to evaluate the rate and the predictors of axillary lymph node metastasis in patients with T1mi breast cancer. Methods: We analyzed 62 cases of ductal carcinoma in situ with microinvasion, and the pathology records and treatment charts were retrospectively reviewed for information on the patient and tumor characteristics. All the included patients underwent breast conserving surgery and 48 patients underwent axillary lymph node dissection. Results: The incidence of axillary involvement was 8.3%. Comedo ductal carcinoma in situ (P ¼ 0.031), histologic grade 3 (P ¼ 0.025), the presence of necrosis (P ¼ 0.007) and Van Nuys group 3 (P ¼ 0.025) were significant predictors of axillary involvement on the statistical analysis. Axillary dissection was significantly associated with the occurrence of arm lymphedema (P ¼ 0.030). Conclusions: A significant rate of axillary metastases occurred in the patients with T1mi breast carcinoma in this study. The comedo subtype of ductal carcinoma in situ, a high histologic grade, the presence of necrosis and the Van Nuys group 3 were significant predictors of axillary lymph node metastasis in patients with T1mi breast cancer. Thus, the patients with T1mi breast disease are indicated to a careful evaluation of axillary lymph node metastasis, if they have the earlier-mentioned unfavorable factors.
INTRODUCTION
The treatment of microinvasive breast cancer (T1mi) has received little attention in the past since it was a very rare disease entity in patients with breast carcinomas. However, mammographic screening programs have increased the detection of ductal carcinoma in situ (DCIS) and also DCIS with microinvasion. DCIS currently accounts for 12 -15% of all the newly diagnosed cases of breast cancer annually, and 5.1 -13.5% of all DCISs have a microinvasive component (1) . A wide range of diagnostic criteria has been used in published studies for the evaluation of microinvasion. The microinvasion has been defined in various ways such as DCIS with the evidence of stromal invasion (2) , DCIS with limited microscopic stromal invasion below the basement membrane, but not invading .10% of the surface of the examined histologic sections (3), one or two microscopic foci of possible invasion not .1 mm in the greatest dimension (1), a single focus of invasive carcinoma ,2 mm, or up to three foci of invasion with each not more than 1 mm in the greatest dimension (4) and the maximal extent of invasion is not more than 2 mm or it comprises ,10% of the tumor, with .90% of DCIS (5) . In 1997, the American Joint Committee on Cancer (AJCC) defined microinvasive breast cancer as the extension of cancer cells beyond the basement membrane into the adjacent tissues, with no single focus larger than 1 mm in the greatest dimension (6) . When the intensive component is 1 -5 mm in its greatest dimension, the tumor is classified as T1a. This system refers only to the largest invasive component and it ignores the size of the DCIS and the number of invasive foci. This diversity in the histopathologic definition may explain the 0 -22% range of the reported rates of axillary lymph node metastasis (ALNM) in patients with microinvasive breast carcinoma (7, 8) .
The presence of any focal invasion within the stroma surrounding the DCIS may be associated with metastatic foci. ALNM is the most important prognostic factor in breast cancer, and ALNM serves as an indicator for systemic adjuvant therapy (9) . Sentinel lymph node biopsy (SLNB) with consecutive axillary lymph node dissection (ALND) of the level I -II axilla in positive SLNB is the standard management for staging and treatment of invasive breast cancer (10). ALND is not generally recommended for DCIS, and its role in DCIS with microinvasion has not yet been established since any solid data on this subject are scarce. The aim of this study is to evaluate the rate of ALNM and identify its predictors in patients with T1mi breast cancer in order to recognize the patients who are at a higher risk of axillary dissemination and for whom axillary nodal evaluation and adjuvant systemic therapy are indicated.
PATIENTS AND METHODS

PATIENTS
We conducted a review analysis of a prospective database for all the patients who were diagnosed with invasive breast carcinoma or DCIS treated at St. Vincent's Hospital, College of Medicine, The Catholic University of Korea between January 1999 and January 2011. Institutional review board approval was obtained before the record review. Pathology records and treatment charts of primary breast cancer and pure DCIS patients were retrospectively reviewed for information on the patient and tumor characteristics. From this group of patients, a total of 67 patients were considered to have T1mi breast disease. None of these patients received preoperative chemotherapy or radiotherapy. All the included patients underwent breast conserving surgery and 48 patients underwent ALND (level I -II). Five patients were excluded from our study because the size of the tumor focus was more than 1 mm in the greatest diameter at the time of evaluation. Thus, 62 cases were ultimately analyzed in this study.
CLINICAL EVALUATION AND MEASUREMENT OF THE LYMPHEDEMA
The clinical information included age, tumor palpability and the presence of microcalcification on the mammographic finding. All the patients had undergone preoperative mammography. A lesion was recorded as palpable if it could be felt by at least one examiner prior to radiographic identification, and it was scored as non-palpable if the physical examination was recorded as negative for palpation and the lesion was discovered by mammography.
Measurements of the ipsilateral and contralateral arm circumferences at 15 cm below the acromion process and 15 cm below the olecranon were performed within 30 days after radiotherapy and then every 3 months for the first 2 years and then every 6 months thereafter. An increase in arm circumference by 2 cm or more in the ipsilateral arm, either above or below the elbow, was considered diagnostic of ipsilateral arm lymphedema.
RADIOTHERAPY
All the 62 patients who were included in this study received radiation to the breast with using an isocentric technique. The superior extent of these fields typically included the lower level I lymph nodes. The irradiation schedule was 5 days/week at 1.8 Gy/fraction and it was given with 6-MV photons. The prescribed irradiation dose was 50.4 Gy in 28 fractions to the whole breast, and an additional tumor bed boost of 9 Gy in five fractions was delivered. An en-face electron field was commonly used for boosting the tumor bed.
HISTOPATHOLOGIC EXAMINATION
The histopathologic characteristics that were evaluated included the tumor size, the Ki-67 score, the architectural subtype, the histologic grade, the presence of tumor necrosis, the Van Nuys grouping, the estrogen receptor (ER) and progesterone receptor (PR) statuses as well as the epidermal growth factor receptor 1 (EGFR1) and human epidermal growth factor receptor 2 (Her2) expressions. All the slides that were used for the pathology reports of DCIS or DCIS with microinvasion were reviewed by an experienced pathologist who has specialized in breast pathology. The tumor size was determined using the largest dimension of the invasive and non-invasive components as measured in the gross pathologic specimen and that were categorized as T1mi by using the 1997 cancer staging manual put forth by the AJCC (6) . Each focus of microinvasion was measured using an ocular micrometer and the number of focuses was also calculated. Each case was subclassified into one of the five histopathologic subtypes (comedo, solid, cribriform, micropapillary and papillary). We adopted the Van Nuys' classification system for the classification of the in situ components (11) . The cases were defined in three groups: a non-high nuclear grade without necrosis (Group 1), a non-high nuclear grade with necrosis (Group 2) and a high nuclear grade (Group 3) according to Van Nuys' system. Immunohistochemistry (IHC) analysis was performed on the formalin-fixed, paraffin-embedded breast cancer tissue. The ER and PR analysis was based on an IHC assay, in which a report of 10% or greater of the cells that had nuclear staining for either ER or PR was defined as positive. IHC was performed with anti-ER (Thermo, clone: SP1, dilution: 1:100, Fremont, CA, USA) and anti-PR (Thermo, clone: SP2, dilution: 1:100) by an autostaining system. Breast cancer tumors were classified as Her2-positive if they demonstrated Her2 gene amplification using the fluorescence in situ hybridization method, or they were scored as 3þ by the IHC method. The intensity of the membrane staining was defined by a semiquantitative score (0 to 3þ). The tumor staining was compared with the staining of the normal breast epithelium from the same patient as a negative control. For clinical purposes, 3 þ staining, which was defined as uniform and intense membrane staining in more than 30% of the invasive breast cancer cells, was considered as overexpression. Scoring of Ki-67 in the cancer cells was performed on high-power fields (Â400) using a standard microscope. In each case, approximately 1000 carcinoma cells were counted, and the percentage of immunoreactivity was determined. We defined node positivity (þ) as one or more histologically documented axillary lymph nodes.
STUDY DESIGN AND STATISTICAL ANALYSIS
Relapse-free survival (RFS) was measured from the date of histologic or cytologic confirmation to the date of the first observation of disease recurrence or death. Overall survival was measured from the date of histologic or cytologic confirmation to the date of death from any cause or the most recent follow-up.
Pearson's x 2 test, Fisher's exact test or a t-test was used to evaluate the relationship between the clinical and pathologic variables and the ALNM status. Unadjusted odds ratios (ORs), 95% confidence intervals (CIs) and P values were calculated. Statistical significance was evaluated at the 0.05 alpha level. All the tests were two-sided. Table 1 shows the patient and treatment characteristics. All the 62 patients were Korean women. The median age of all the included patients was 49 years (range: 25 -76 years). All the patients had undergone breast conserving surgery with or without ALND, and they also received adjuvant irradiation to the breast. There were 14 patients who had initially undergone a lumpectomy, and they also received additional surgery because of positive margins. Axillary involvement was detected in four patients of the axillary-dissected group, and the four patients with positive axillary nodes had received adjuvant chemotherapy. The most frequent histologic type was the comedo subtype of DCIS (21 patients), followed by cribriform subtype of DCIS (13 patients).
RESULTS
PREDICTORS OF POSITIVE AXILLARY LYMPH NODES
Of the 62 patients with T1mi disease, 48 underwent ALND. Four of them had ALNM and so the incidence of axillary involvement was 8.3%. The mean number of excised lymph nodes was 12.6. Fourteen patients who did not undergo an axillary dissection were excluded from the statistical analysis because their axillary statuses were unknown. The mammographic finding of microcalcification (30 patients) was the most frequent sign at presentation, followed by a palpable mass (17 patients). These presenting signs had no correlation with the presence or absence of ALNM. The relationship between the pathologic variables and the ALNM status is presented in Table 2 , and the ORs and the 95% CIs are presented in Table 3 . Four variables were found to be significant on the statistical analysis. These included the comedo subtype of DCIS, histologic grade 3, the presence of necrosis 1164 Lymph node metastasis for T1mi breast cancer and Van Nuys group 3. Seventeen (38.6%) of the nodenegative 44 patients treated with ALND had the comedo subtype of DCIS, and all 4 patients with ALNM had the comedo subtype of DCIS. The comedo subtype of DCIS was significantly associated with an increased risk of ALNM (P ¼ 0.031). A higher histologic grade was significantly associated with nodal disease (P ¼ 0.025). The presence of necrosis was a significant factor for ALNM (P ¼ 0.007), with 100% of the patients with ALNM having tumor necrosis compared with only 25.0% of the node-negative patients. The patients of Van Nuys group 3 have a more significantly increased probability of ALNM than that of the patients of Van Nuys group 1 -2 (P ¼ 0.025). However, not only the ER, PR and Her2 statuses, but also the tumor size and Ki-67 score were not significantly associated with the ALNM status in the patients with T1mi breast carcinoma.
THE INCIDENCE OF ARM LYMPHEDEMA
At least one set of arm measurements was available for the eligible patients who had lumpectomy with or without ALND plus postoperative irradiation. Table 4 shows the incidence of arm lymphedema in the patients who had undergone lumpectomy with or without ALND and who had received adjuvant radiotherapy. There were 19 patients who experienced arm edema during their periods of follow-up. For axillary-dissected and non-axillary-dissected group, arm edema was recorded at least once in 18 (37.5%) and 1 (7.1%) patients, respectively. ALND was significantly associated with the occurrence of arm lymphedema (P ¼ 0.030).
RECURRENCE AND SURVIVAL
One patient who had undergone ALND was unavailable for follow-up, and two patients died of unrelated causes (myocardinal infarction and stroke) during the follow-up period. None of the patients with ALND experienced locoregional relapse or distant metastases during the follow-up period. One patient who did not undergo ALND developed axillary relapse 2 year after the breast irradiation. She is now free of disease after her second surgery. The remaining patients were alive and free of disease at the time of last follow-up. The median follow-up period for all the patients was 58 months (range: 6 -128 months). The 5-year survival rate was 94.6%, and 5-year RFS rate was 92.2% (Fig. 1) .
DISCUSSION
Over the past two decades, the widespread use of mammographic screening for breast carcinoma has increased the detected incidence of DCIS, as well as increasing the detection of early breast cancer, including microinvasive breast cancer. For our study, the definition of T1mi is based on the 1997 AJCC staging classification for breast carcinomas, and we have characterized the clinical, pathological and immunohistochemical features associated with this lesion, which is a rare disease. The incidence of microinvasive carcinoma of the breast has been reported to be ,1% of all breast cancers, 1.06% of all infiltrating carcinoma and 5.1 -13.5% of all in situ carcinoma (1, 12) . The median age of the patients in our study was 49 years, which was younger than the median age of other studies (range: 56 -61 years) (4, 5, 13) , suggesting that we should pay attention to younger patients who are diagnosed with DCIS, whether or not there is stromal microinvasion. Silverstein and Lagios reported that the patients with DCIS and microinvasion tended to have involved margins after their initial surgeries (14) . Our series showed that 14 (22.5%) patients had an involved margin after the initial operation.
A common route of spread of breast carcinoma is first through the axillary lymph nodes, and the incidence of ALNM is increasing with the larger tumors in patients with small breast carcinomas (13) . The method of determining the tumor size varies among investigators, with some Jpn J Clin Oncol 2011;41(10) 1165
including the DCIS component and others do not. We used the non-invasive and invasive components, and the tumor size was not a significant predictor of ALNM. In our study, the significant predictors of ALNM were the comedo subtype of DCIS, histologic grade 3, the presence of necrosis and the Van Nuys group 3. The comedo subtype of DCIS was reported in 38% of the cases in the study by Wasserberg et al. (15) , and it suggests that a high nuclear grade, comedo DCIS and a high number of DCIS-involved ducts may predict ALNM and this should be considered when axillary dissection is done selectively. Comedo DCIS was the dominant histological finding in 21 (33.8%) of the 62 T1mi tumors in our study and this was significantly correlated with positive axillary nodes. The Van Nuys classification combines a high nuclear grade and comedo-type necrosis to predict clinical tumor recurrences, and it defines three distinct and easily recognizable groups. The patients of Van Nuys group 1 (non-high grade with non-comedo-type necrosis) have higher disease-free survival than do the patients of Van Nuys groups 2 and 3 (11). Similarly, a higher nuclear grade is a well-known risk factor for ALNM in the patients with small breast cancers, in accordance with a number of published studies (13, 15) . The surgical management of microinvasive carcinoma, and particularly the management of the axilla, has been controversial. Some believe that ALND is not necessary for DCIS with microinvasion because it is generally not associated with ALNM, and DCIS has a favorable natural history (16) . Others have reported rates of ALNM ranging from 2.7 to 20% and they advocate complete ALND (17, 18) . In 2010, NSABP B-32 trial suggested that in patients with negative SLNB, SLNB alone (with no further ALND) was a satisfactorily appropriate, safe and effective therapy for patients with early breast cancer (10) .
ALND is associated with a significant postoperative morbidity such as arm pain, arm lymphedema and shoulder stiffness (19) , and it does not improve the long-term survival for patients with small breast cancers (7, 10) . In our study, ALND significantly increased the incidence of arm lymphedema (37.0 vs 7.1%, P ¼ 0.030). SLNB reduces the incidence of complications such as arm edema and delayed wound healing and it is not associated with an increased risk of regional recurrence. Thus, SLNB has also been used in patients with early breast cancer. The rate of predicting the axillary nodal status has ranged from 95 to 100%, with falsenegative rates ranging from 1 to 15% (20, 21) . However, in our institution, the patients with early breast carcinomas do not routinely undergo SLNB under the rationale that it, being a time-consuming procedure, may lead to unnecessarily prolonged operative time. Besides, a multidisciplinary team composed at least of a surgeon, a nuclear medicine specialist, a radiologist and a pathologist is required for this single procedure. The frozen section evaluation in SLNB is known to have a false-negative rate of 15 -20%, which is relatively high in context of determining a second surgery. All of the earlier-mentioned raises a reasonable doubt of efficacy regarding the cost and time. Nonetheless, noninstitutionalized SLNB is one weak point of our study (22, 23) .
Axillary irradiation may also serve as an alternative to ALND for clinically node-negative patients, with similar recurrence rates reported for both modes of treatment (23) , and there is up to a 50% reduction of the ALND-related morbidity with axillary irradiation (24) . However, axillary irradiation does not provide information on the nodal status (25) .
In conclusion, the incidence of positive axillary nodes was 8.3% for the patients with T1mi breast cancer in our retrospective study. The comedo subtype of DCIS, a high histologic grade, the presence of necrosis and the Van Nuys group 3 may significantly predict axillary metastases. Therefore, the patients with T1mi breast disease are indicated to a thorough evaluation of ALNM, if they have the earlier-mentioned unfavorable factors. 
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